DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Morita M, Tamiya M, Fujimoto D. et al.
Prediction of patients with a tumor proportion score 50 % who do not respond to first-line monotherapy with pembrolizumab.
BMC Cancer 2020;
20: 93
DOI: 10.1186/s12885-020-6582-4.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.